BDX BCAL Diagnostics Limited
Healthcare · Diagnostics & Research
· website
$0.07
52wk 0.05 – 0.15
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About BCAL Diagnostics Limited
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTESTplus, a first-in-class blood test designed to be used alongside standard mammogram in breast cancer screening. The company also develops BREASTEST, BCAL Diagnostics, and BCAL Dx. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$24.70M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.02
Dividend yield
—
Payout ratio
0.0%
Beta
0.81
EV / EBITDA
-3.86
Price / Book
9.57
ROE
-121.7%
Operating margin
-289.6%
Net margin
-282.1%
Total cash
$3.33M
Total debt
$3.44M
Current ratio
3.67
Debt / Equity
1.38
Free cash flow
$-3.83M
Avg volume
359,639
Latest annual results
(FY ending 30 Jun 2025)
- Revenue$21.64K
- Gross profit$21.64K
- Operating income-$9.96M
- Net income-$7.24M
- Diluted EPS-0.02
- Free cash flow-$6.92M
- Net debt-$2.14M